AU5845594A - Cancerous b cell treatment using substituted nucleoside derivatives - Google Patents

Cancerous b cell treatment using substituted nucleoside derivatives

Info

Publication number
AU5845594A
AU5845594A AU58455/94A AU5845594A AU5845594A AU 5845594 A AU5845594 A AU 5845594A AU 58455/94 A AU58455/94 A AU 58455/94A AU 5845594 A AU5845594 A AU 5845594A AU 5845594 A AU5845594 A AU 5845594A
Authority
AU
Australia
Prior art keywords
cancerous
cell treatment
substituted nucleoside
nucleoside derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58455/94A
Inventor
Michael G. Goodman
Lawrence D Piro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU5845594A publication Critical patent/AU5845594A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU58455/94A 1992-11-13 1993-11-12 Cancerous b cell treatment using substituted nucleoside derivatives Abandoned AU5845594A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97583092A 1992-11-13 1992-11-13
US975830 1992-11-13
US151142 1993-11-12
PCT/US1993/010898 WO1994011003A1 (en) 1992-11-13 1993-11-12 Cancerous b cell treatment using substituted nucleoside derivatives

Publications (1)

Publication Number Publication Date
AU5845594A true AU5845594A (en) 1994-06-08

Family

ID=25523453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58455/94A Abandoned AU5845594A (en) 1992-11-13 1993-11-12 Cancerous b cell treatment using substituted nucleoside derivatives

Country Status (2)

Country Link
AU (1) AU5845594A (en)
WO (1) WO1994011003A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
JP2001501600A (en) * 1996-09-10 2001-02-06 ザ バーナム インスティテュート Tumor homing molecules, conjugates derived therefrom, and methods of using the same
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
CR20200649A (en) 2018-05-25 2021-05-11 Primmune Therapeutics Inc Tlr7 agonists
IL293293A (en) 2019-11-26 2022-07-01 Primmune Therapeutics Inc Tlr7 agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643992A (en) * 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4539205A (en) * 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4948730A (en) * 1982-11-09 1990-08-14 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
ATE57187T1 (en) * 1983-03-30 1990-10-15 Lilly Industries Ltd VINCALEUKOBLASTIN DERIVATIVES.
US4746651A (en) * 1983-11-01 1988-05-24 Scripps Clinic And Research Foundation Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives
US4724213A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies

Also Published As

Publication number Publication date
WO1994011003A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
AU3978689A (en) Nucleoside derivatives
AU2883989A (en) Avermectin derivatives
AU2867189A (en) Dideoxydidehydrocarbocyclic nucleosides
AU1444488A (en) Therapeutic nucleosides
AU3388893A (en) Pyrimidine derivatives
AU8038491A (en) Purine derivatives
AU1480497A (en) Cancer treatment
AU617210B2 (en) Therapeutic nucleosides
AU3526989A (en) 2-amino-pyrimidine derivatives
AU5737494A (en) Human thrombospondin-4
AU5340594A (en) Skin treatment
AU5845594A (en) Cancerous b cell treatment using substituted nucleoside derivatives
AU3170293A (en) Therapeutic nucleosides
AU1318588A (en) Therapeutic nucleosides
AU4508493A (en) Therapeutic nucleosides
AU3607189A (en) Pyrimidine derivatives
AU3719489A (en) Purine derivatives
AU3434489A (en) Skin treatment formulations
AU4334297A (en) Antiviral treatment
AU2200092A (en) Therapeutic nucleosides
AU7112891A (en) Therapeutic nucleosides
AU5165993A (en) Pp14-based therapy
AU2641192A (en) Therapeutic nucleosides
AU632369C (en) Therapeutic nucleosides
AU632369B2 (en) Therapeutic nucleosides